Journal of Shanghai University >
Circulating miRNAs predict response to cardiac resynchronization therapy
Received date: 2016-06-13
Online published: 2016-06-30
Supported by
National Institutes of Health (NCATS UH3 TR000901)
Heart failure (HF) is one of the most common syndrome seriously harmful to human health. Cardiac resynchronization therapy (CRT) is an exciting recent advancement for HF patient by targeting ventricular systolic dyssynchrony, but it has been proved that CRT cannot achieve hemodynamic or clinical benefit for all patients. It is very essential to find out biomarkers for predicting responsive patients. Circulating extracellular microRNAs(miRNAs) have emerged as novel biomarkers for many diseases. Recent study indicated that a high level of circulating miR-30d could predict response to CRT, which may have bright prospects in future research and application.
Key words： biomarker; microRNAs; cardiac resynchronization therapy
WANG Fei, Saumya Das . Circulating miRNAs predict response to cardiac resynchronization therapy[J]. Journal of Shanghai University, 2016 , 22(3) : 265 -269 . DOI: 10.3969/j.issn.1007-2861.2016.04.019
[1] Writing G M, Mozaffarian D, Benjamin E J, et al. Heart disease and stroke statistics—2016 update: a report from the American Heart Association [J]. Circulation, 2016, 133(4): e38-e60.
[2] DeVore A D, Hammill B G, Sharma P P, et al. In-hospital worsening heart failure and associations with mortality, readmission, and healthcare utilization [J]. Journal of the American
Heart Association, 2014, DOI: 10.1161/JAHA.114.001088.
[3] Jaffe M L, Morin D P. Cardiac resynchronization therapy: history, present, status, and future directions [J]. The Ochsner Journal, 2014, 14: 596-607.
[4] Shenkman H J, Pampati V, Khandelwal A K, et al. Congestive heart failure and QRS duration: establishing prognosis study [J]. Chest, 2002, 122(2): 528-534.
[5] Cazeau S, Ritter P, Bakdach S, et al. Four chamber pacing in dilated cardiomyopathy [J]. Pacing and Clinical Electrophysiology: PACE, 1994, 17(11Pt2): 1974-1979.
[6] Kass D A, Chen C H, Curry C, et al. Improved left ventricular mechanics from acute VDD pacing in patients with dilated cardiomyopathy and ventricular conduction delay [J]. Circulation, 1999, 99(12): 1567-1573.
[7] Auricchio A, Stellbrink C, Block M, et al. Effect of pacing chamber and atrioventricular delay on acute systolic function of paced patients with congestive heart failure [J]. Circulation, 1999, 99(23): 2993-3001.
[8] Bax J J, Gorcsan J. Echocardiography and noninvasive imaging in cardiac resynchronization therapy: results of the PROSPECT (Predictors of Response to Cardiac Resynchronization Therapy) study in perspective [J]. Journal of the American College of Cardiology, 2009, 53(21): 1933-1943.
[9] Birnie D H, Tang A S. The problem of non-response to cardiac resynchronization therapy [J]. Current Opinion in Cardiology, 2006, 21(1): 20-26.
[10] Kirk J A, Kass D A. Electromechanical dyssynchrony and resynchronization of the failing heart [J]. Circulation Research, 2013, 113(6): 765-776.
[11] Yu C M, Sanderson J E, Gorcsan J. Echocardiography, dyssynchrony, and the response to cardiac resynchronization therapy [J]. European Heart Journal, 2010, 31(19): 2326-2337.
[12] Tanaka H, Nesser H J, Buck T, et al. Dyssynchrony by speckle-tracking echocardiography and response to cardiac resynchronization therapy: results of the Speckle Tracking and Resynchronization (STAR) study [J]. European Heart Journal, 2010, 31(14): 1690-1700.
[13] Chung E S, Leon A R, Tavazzi L, et al. Results of the predictors of response to CRT (PROSPECT) trial [J]. Circulation, 2008, 117(20): 2608-2616.
[14] Ono K, Kuwabara Y, Han J. MicroRNAs and cardiovascular diseases [J]. The FEBS Journal, 2011, 278(10): 1619-1633.
[15] Xiao J. MicroRNA therapeutics [J]. Mini Reviews in Medicinal Chemistry, 2015, 15(6): 440.
[16] Zhou L, Zang G, Zhang G, et al. MicroRNA and mRNA signatures in ischemia reperfusion injury in heart transplantation [J]. PLoS One, 2013, 8(11): e79805.
[17] Mendell J T, Olson E N. MicroRNAs in stress signaling and human disease [J]. Cell, 2012, 148(6): 1172-1187.
[18] Marfella R, Di Filippo C, Potenza N, et al. Circulating microRNA changes in heart failure patients treated with cardiac resynchronization therapy: responders vs. non-responders [J].
European Journal of Heart Failure, 2013, 15(11): 1277-1288.
[19] Melman Y F, Shah R, Danielson K, et al. Circulating microRNA-30d is associated with response to cardiac resynchronization therapy in heart failure and regulates cardiomyocyte apoptosis: a translational pilot study [J]. Circulation, 2015, 131(25): 2202-2216.
/
| 〈 |
|
〉 |
